Literature DB >> 33135423

Facial Nerve Paralysis Following Endovascular Embolization: A Case Report and Review of the Literature.

Austin Y Feng1, Michael C Jin1, Sandy Wong1, Jon-Paul Pepper1, Robert Jackler1, Yona Vaisbuch1.   

Abstract

OBJECTIVE: We report a case of facial nerve paralysis post-endovascular embolization of a sigmoid sinus dural arterio-venous fistula from initial presentation to current management and discuss the merits of observation versus decompression through a systematic review of relevant literature. PATIENT: 61 F with right facial palsy. INTERVENTION: Following a single intravenous dexamethasone injection with oral steroids over 2 months, patient was observed with no additional treatment other than Botox chemodenervation and facial rehabilitation. OUTCOME AND
RESULTS: The patient initially presented with complete right facial palsy (HB 6/6). Post-op CT imaging indicated Onyx (ev3, Irvine, California, USA) particles present at the geniculate segment of the facial nerve. Observation was chosen over surgical intervention. At the most current follow up of 8 months, facial function has improved substantially (HB 2/6).
CONCLUSION: Facial palsy is a serious, though rare, complication of transarterial endovascular embolization. With our case report and literature review, we highlight not only how conservative observation is the recommended treatment, but also that facial nerve recovery should be expected to reach near complete recovery, but not sooner than in 3 months.

Entities:  

Keywords:  ONYX; embolization; facial nerve palsy

Mesh:

Year:  2020        PMID: 33135423     DOI: 10.1177/0003489420966611

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  1 in total

1.  Newly Prepared 129Xe Nanoprobe-Based Functional Magnetic Resonance Imaging to Evaluate the Efficacy of Acupuncture on Intractable Peripheral Facial Paralysis.

Authors:  Fengyun Fan; Xiaonan Wang; Yao Lu; Kaixue Jia
Journal:  Contrast Media Mol Imaging       Date:  2022-03-10       Impact factor: 3.161

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.